Register for More Information

Register Now

Contact an Account Manager

Contact Now

Find a Treatment Center

Enter your state or zip code to find a THERAKOSTM Photopheresis treatment center near you

Talk to your doctor to determine if treatment is right for you

 
 
 

Types of CTCL

Types of CTCL

Types of CTCL

Cutaneous T-cell lymphoma (CTCL) is an umbrella term used to describe several related lymphomas. The most common forms—and the first to be identified—are Mycosis fungoides and Sézary syndrome. The term, however, now includes a number of additional diseases characterized by malignant T cell expansions.

Mycosis Fungoides (MF)

MF is the most common form of CTCL, accounting for 50% to 60% of all cases.17,18

MF has an indolent course, with slow progression over many years or decades. It typically progresses from patches to plaques, and eventually to tumor development.17

While MF is generally limited to epidermal involvement, in some patients the disease slowly spreads to the lymph nodes and internal organs.17

Sézary syndrome (SS)

SS is an aggressive form of disease that affects approximately 5% of patients with CTCL.18

Additional CTCL classifications17

Other, less common forms of CTCL may be categorized according to their clinical form—indolent and aggressive. THERAKOS™ Photopheresis has not been evaluated in these less common forms.

Indolent form

  • MF variants and subtypes
    • Folliculotropic MF
    • Pagetoid reticulosis
    • Granulomatous slack skin
  • Primary cutaneous CD30+ lymphoproliferative disorders
    • Primary cutaneous anaplastic large cell lymphoma
    • Lymphomatoid papulosis
  • Subcutaneous panniculitis-like T-cell lymphoma
  • Primary cutaneous CD4+ small/medium pleomorphic T-cell lymphomas

Aggressive clinical form

  • Primary cutaneous NK/T-cell lymphoma, nasal type
  • Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma (provisional)
  • Primary cutaneous γ/δ T-cell lymphoma (provisional)
  • Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma (provisional)
 

Important Safety Information

Indications

Methoxsalen Sterile Solution is indicated for extracorporeal administration with the THERAKOS UVAR XTS® or THERAKOS CELLEX® Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment.

Methoxsalen should be used only by physicians who have special training in the THERAKOS UVAR XTS® or THERAKOS CELLEX® Photopheresis Systems. Methoxsalen is contraindicated in patients exhibiting idiosyncratic reactions to psoralen compounds, patients with a specific history of a light sensitive disease, or patients with aphakia.

THERAKOS Photopheresis is not appropriate for patients who cannot tolerate extracorporeal volume loss or shifts, or patients with coagulation disorders. See Important Safety Information for additional details.

 
 

All contents Copyright © Therakos, Inc. 2001-2013.

This site is published by Therakos, Inc. which is solely responsible for its contents.

It is intended for visitors from the United States of America.